IMMUNIC, INC. Files 8-K: Board Changes and Executive Compensation Updates
Ticker: IMUX · Form: 8-K · Filed: Jul 24, 2024 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Jul 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
TL;DR
IMMUNIC board shakeup & pay changes filed. #CorpGov
AI Summary
On July 21, 2024, IMMUNIC, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers, alongside financial statement disclosures and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board positions, coupled with financial disclosures, can introduce uncertainty about future strategic direction and operational stability.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- July 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1200 Avenue of the Americas, Suite 200 New York, NY 10036 (address) — Principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but the specific names and details of any departures or new appointments are not detailed in the provided excerpt.
What are the key items disclosed in the financial statements and exhibits?
The filing states that financial statements and exhibits are included, but the specific content of these documents is not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated July 21, 2024.
What is IMMUNIC, INC.'s principal executive office address?
The principal executive offices are located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
What is the SIC code for IMMUNIC, INC.?
The Standard Industrial Classification (SIC) code for IMMUNIC, INC. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 954 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2024-07-24 06:40:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
- $1 — ons have an exercise price per share of $1.46, the closing price of the Company's
Filing Documents
- e663800_8k-immunic.htm (8-K) — 25KB
- e663800_ex99-1.htm (EX-99.1) — 15KB
- image.jpg (GRAPHIC) — 6KB
- 0001193805-24-000957.txt ( ) — 226KB
- imux-20240721.xsd (EX-101.SCH) — 3KB
- imux-20240721_lab.xml (EX-101.LAB) — 33KB
- imux-20240721_pre.xml (EX-101.PRE) — 22KB
- e663800_8k-immunic_htm.xml (XML) — 4KB
02. Departure of Directors or Principal Officers; Election
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 24, 2024, Immunic, Inc. (the "Company") announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the "Board") of the Company, effective as of July 22, 2024. As a Class I director, Ms. Skerjanec's term lasts until the Company's 2027 annual meeting of stockholders (the "Annual Meeting"). Ms. Skerjanec, age 60, has nearly thirty years of global experience in the pharmaceutical industry overseeing product commercialization and business strategy initiatives. From March 2015 until December 2023, Ms. Skerjanec held several leadership positions at Roche in Switzerland, where she most recently served as Senior Vice President, Global Head of Neuroscience and Rare Diseases. In this role, Ms. Skerjanec led business and global corporate strategy for Roche's portfolio of neurological and rare diseases. Previously, Ms. Skerjanec served as General Manager of Roche in Portugal and served as the Neuroimmunology Franchise Head where she was in charge of certain drug commercialization efforts on behalf of the company. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular Franchise Head at The Medicines Company where she held various roles in development and commercialization from July 2003 to February 2015. Before her employment at The Medicines Company, Ms. Skerjanec held positions at Eli Lilly, Pfizer, and Johnson & Johnson. Since May 2024, Ms. Skerjanec has served on the board of directors of Avidity Biosciences. Ms. Skerjanec received her M.Pharm from the University of Ljubljana School of Pharmacy and her MBA from Fairleigh Dickinson University. The Nominating and Corporate Governance Committee and the Board believe that Ms. Skerjanec's expertise and decades-long management of research and development and product commercialization efforts in t
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description of Exhibit 99.1 Press release dated July 24, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: July 24, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer